HIRONIC Expands Presence in Indonesian Market with ‘New Doublo 2.0’
SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ -- HIRONIC, a leading provider of aesthetic medical devices, announced on the 19th that it has obtained certification from the Indonesian Ministry of Health (KEMENKES RI) for its flagship product, New Doublo 2.0—a state-of-the-art device combining 4th-generation High-Intensity Focused Ultrasound (HIFU) and Radiofrequency (RF) technologies in a single treatment platform. This approval...
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches in Malaysia and India BANGKOK, Aug. 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval...
Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids
SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA). This marks not only a milestone event in China's assisted reproductive field but also signifies that domestically produced high-end culture media have...
Fullerton Health Announces Strategic Investment by Mitsubishi Corporation
SINGAPORE, Aug. 26, 2025 /PRNewswire/ -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets across Asia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This partnership marks a significant milestone in Fullerton Health's growth journey, enabling greater...
MORROW founder invests US $156m and launches new flagship in Singapore as US $8 trillion longevity revolution ramps up
SINGAPORE, Aug. 26, 2025 /PRNewswire/ -- Entrepreneur Allen Law is to open MORROW, a 38,000 sq ft centre that empowers individuals to adopt a healthy lifestyle with a personalised roadmap, supported by a team of professionals and coaches, as part of his global mission to increase the human healthspan. US $156m (SGD $200m) will...
Infinitus Named in Liaowang Institution’s “Leading Transparent Factory Case Studies”
GUANGZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen, Guangdong from August 19-20, 2025. During the event, Xinhua News Agency's national high-end think tank,...
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8%...
Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer will be participating in person at investor conferences in New York City. Morgan Stanley 23rd Annual Global Healthcare Conference Date:...
Peijia Medical Announces 2025 Interim Results
HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025. The Group reported sustained revenue growth and significantly improved...
Acceleration in Clinical Development! Leads Biolabs’ LBL-034 Dosed First Patient in Phase Ⅱ Trial
NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data. This milestone endows LBL-034 with the potential to become the first domestic T-cell engager (TCE) therapy...
